Drug Discovery Technology using Human iPS Cells



July 17, 2012

Joseph A. Frank, Chief, Frank Laboratory, National Institutes of Health

Human iPS cell technology is expected to become a mainstream of drug discovery, which allows a mid-high throughput cell-based assay using human native cells derived from iPS cells.iPS cells can be expanded in vitro infinitely and then can be differentiated to various types of native cells including cardiomyocytes, neural cells, and hepatocytes, which means unlimited supply of human native cells in large scale. We succeeded in releasing to the market iPSC-derived cardiomyocytes in 2009 which can be applied for toxicity assay using MEA system and Ca imaging systems.In 2010, we launched iPSC-derived dopaminergic neurons which can be applied for Parkinson's disease assay. In addition, we have a plan to launch iPSC-derived hepatocytes in 2012.In this presentation, we would like to share updated information on three types of native cells and the assay technology.

BioengineeringDrug DiscoveryStem Cells

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.